Heron Therapeutics, Inc., a commercial-stage biotechnology company, has relocated its headquarters from San Diego, California, to Cary, North Carolina, according to a recent company announcement.
A majority of Heron's management team and corporate employees work from its Cary office near Research Triangle Park ("RTP"), one of the most prominent high-tech research and development parks in the United States. The growing biotech community in Cary and its surrounding areas provides ample space for growth and expansion, the company said.
Heron focuses on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Heron's portfolio of products aim to advance the standard-of-care for acute care and oncology patients.
For acute care, Zynrelef is used to treat pain in small-to-medium-sized wounds after surgery, and Aponvie is used to prevent postoperative nausea and vomiting in adults. For oncology care, Sustol and Civanti are used to for chemotherapy-induced nausea and vomiting prevention. For more information about Heron's product portfolio, click here.
"We are excited to move our headquarters to Cary, North Carolina, which represents a significant milestone in Heron's journey," said Craig Collard, chief executive officer of Heron.
"This move will not only strengthen our ability to support our employees by centralizing our operations and resources but also positions us in an excellent location from which we can continue making strategic partnerships as we growing our existing portfolio focused on improving the lives of patients in the acute and oncology care settings. This is an exciting chapter for Heron, and we look forward to the continued success and partnerships that lie ahead."